에리스로포이에틴 제제 시장 예측(-2034년) : 종류, 제품 유형, 유통 채널, 용도, 최종사용자, 지역별 세계 분석

According to Stratistics MRC, the Global Erythropoietin Drugs Market is accounted for $15.5 billion in 2026 and is expected to reach $41.8 billion by 2034 growing at a CAGR of 13.2% during the forecast period. Erythropoietin drugs are a class of medications that include recombinant forms of erythropoietin, a hormone produced naturally in the kidneys. These drugs are designed to stimulate and increase the synthesis of red blood cells, making them effective in managing conditions associated with anaemia. Erythropoietin medications treat anaemia symptoms such as weakness, dyspnea, and vertigo by raising red blood cell counts, leading to improved daily functioning for patients.

According to the World Health Organization (WHO), 42% of children under the age of five and 40% of pregnant women worldwide are anemic.

Market Dynamics:

Driver:

Rising prevalence of anaemia

Anaemia is a condition characterized by a decrease in the number of red blood cells or a decrease in the amount of haemoglobin, leading to reduced oxygen-carrying capacity in the blood. EPO drugs play a crucial role in managing anaemia by stimulating the production of red blood cells. Moreover, EPO drugs are often prescribed to cancer patients to manage chemotherapy-induced anaemia and improve their quality of life. The increasing prevalence of these conditions contributes to the overall burden of anaemia in the population, thereby driving the demand for EPO drugs.

Restraint:

Potential adverse effects

The erythropoietin drug market faces potential restraints linked to the occurrence of adverse effects associated with the therapeutic use of these drugs. One significant concern is the risk of cardiovascular events, including thrombosis and hypertension, associated with the administration of erythropoietin drugs. Furthermore, another potential adverse effect is the development of pure red cell aplasia (PRCA), a rare but serious condition characterized by a sudden halt in the production of red blood cells.

Opportunity:

Increased healthcare awareness

Increased healthcare awareness serves as a pivotal driver in the erythropoietin drugs market. As awareness about health conditions, including anemia, continues to rise among patients and healthcare professionals, there is a heightened recognition of the significance of erythropoietin drugs in managing anemia-associated complications. Moreover, patients are increasingly seeking timely and effective treatments for conditions like chronic kidney disease and other disorders where erythropoietin drugs play a vital role. These factors drive market demand.

Threat:

Emerging alternatives

As scientific and medical research progresses, new therapeutic options, including non-pharmacological interventions and alternative drug therapies, are gaining attention and posing a challenge to the dominance of erythropoietin drugs. Moreover, the increasing availability and adoption of biosimilars in the market can lead to pricing pressures and market share competition, impacting the revenue of branded erythropoietin drugs.

Covid-19 Impact

The erythropoietin drug market experienced notable impacts from the COVID-19 pandemic. Non-urgent medical procedures and treatments, including those involving erythropoietin drugs for anaemia, were deferred or delayed, affecting the overall market demand. Additionally, disruptions in the pharmaceutical supply chain, restrictions on movement, and workforce shortages posed obstacles to the production and distribution of erythropoietin drugs.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to hold the largest share. Cancer patients frequently experience anaemia due to the effects of the disease itself or as a side effect of chemotherapy. Erythropoietin drugs, such as epoetin-alfa, are employed to address anaemia in cancer patients by stimulating the production of red blood cells. Moreover, erythropoietin therapies improve the patient's well-being, potentially allowing for more effective cancer treatment by maintaining adequate levels of oxygen-carrying red blood cells.

The biologics segment is expected to have the highest CAGR during the forecast period

The biologics segment is anticipated to have lucrative growth during the forecast period. Biologics are designed to mimic the natural function of erythropoietin in stimulating the production of red blood cells in the bone marrow. Erythropoietin biologics are commonly used to address anaemia associated with chronic kidney disease, cancer chemotherapy, and certain other medical conditions. Additionally, biologics, including erythropoietin-based agents, contribute significantly to patient care by offering targeted and effective treatments for anaemia.

Region with largest share:

North America commanded the largest market share during the extrapolated period owing to robust healthcare infrastructure, technological innovation, and a high prevalence of conditions. The prevalence of anaemia, particularly in CKD patients undergoing dialysis and individuals undergoing cancer treatments, has fuelled the demand for erythropoietin drugs in North America. Moreover, the region is also at the forefront of biotechnological and pharmaceutical research, driving continuous innovation in erythropoietin drug development.

Region with highest CAGR:

Asia Pacific is expected to witness profitable growth over the projection period, owing to its significant contribution to the global pharmaceutical industry. Countries like China and India have emerged as key players in the production and consumption of erythropoietin drugs. The region's pharmaceutical sector benefits from robust research and development activities, fostering innovation and the introduction of new EPO formulations. Additionally, the Asia-Pacific's evolving healthcare infrastructure and increasing healthcare expenditure contribute to the growth of the erythropoietin drug market.

Key players in the market

Some of the key players in the Erythropoietin Drugs Market include Johnson & Johnson Services, Inc., AstraZeneca, Amgen, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer Inc, LG Chem, F. Hoffmann-La Roche Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd, Ranbaxy Laboratories and Roche Diagnostics.

Key Developments:

In November 2023, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage biotechnology company, to accelerate the development of next generation therapeutics in areas of high unmet need, including oncology, immunology and rare diseases.

In September 2023, Sun Pharmaceutical Industries Limited announced that it had entered into a licence agreement with American biopharmaceutical company Pharmazz Inc to commercialise an innovative drug, Tyvalzi (Sovateltide) in India.

In January 2022, Amgen and Generate Biomedicines announced a research collaboration agreement to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities.

In October 2020, Novartis and Molecular Partners AG announced collaboration in the form of an option and license agreement to develop, manufacture and commercialize Molecular Partners' anti-COVID-19 DARPin(R) program, consisting of two therapeutic candidates, MP0420 and MP0423.

Types Covered:

• Biosimilars
• Biologics

Products Covered:

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Other Products

Distribution Channels Covered:

• Online Pharmacy
• Hospital Pharmacy
• Other Distribution Channels

Applications Covered:

• Hematology
• Cancer
• Neurology
• Renal Diseases
• Other Applications

End Users Covered:

• Speciality Clinics
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Erythropoietin Drugs Market, By Type

• 5.1 Introduction
• 5.2 Biosimilars
• 5.3 Biologics

6 Global Erythropoietin Drugs Market, By Product

• 6.1 Introduction
• 6.2 Epoetin-alfa
• 6.3 Epoetin-beta
• 6.4 Darbepoetin-alfa
• 6.5 Other Products

7 Global Erythropoietin Drugs Market, By Distribution Channel

• 7.1 Introduction
• 7.2 Online Pharmacy
• 7.3 Hospital Pharmacy
• 7.4 Other Distribution Channels

8 Global Erythropoietin Drugs Market, By Application

• 8.1 Introduction
• 8.2 Hematology
• 8.3 Cancer
• 8.4 Neurology
• 8.5 Renal Diseases
• 8.6 Other Applications

9 Global Erythropoietin Drugs Market, By End User

• 9.1 Introduction
• 9.2 Speciality Clinics
• 9.3 Hospitals
• 9.4 Other End Users

10 Global Erythropoietin Drugs Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Johnson & Johnson Services, Inc.
• 12.2 AstraZeneca
• 12.3 Amgen, Inc.
• 12.4 Novartis AG
• 12.5 Teva Pharmaceutical Industries Ltd.
• 12.6 Pfizer Inc
• 12.7 LG Chem
• 12.8 F. Hoffmann-La Roche Ltd.
• 12.9 Sun Pharmaceutical Industries Ltd.
• 12.10 Intas Pharmaceuticals Ltd.
• 12.11 Dr. Reddy's Laboratories Ltd
• 12.12 Ranbaxy Laboratories
• 12.13 Roche Diagnostics